ALB and neoplasm: As depicted in Figure 1a, HSA can traverse tumor vessels via abnormal leaky junctions (the enhanced permeability and retention (EPR) effect; passive targeting) or interact with the caveolin-1 receptor (active targeting), positioning HSA-ZW800-PEG as a significant candidate for robust tumor targeting compared to noncovalently adsorbed ICG:HSA.